A benefits strategy that says no to medication without providing a credible, evidence-based alternative can create frustration, perceived inequity, and disengagement
not just your weight, but the underlying factors driving it
Objective In this narrative overview, the following selection criteria were used: Inclusion criteria included (a) journal reports and/or reviews of clinical studies using pre-, peri-, or postmenopausal women in combination(s) with collagen, hyaluronic acid, curcumin, glutathione, and estrogen deficiency and (b) articles from 2020 to 2025
These assays enable precise functional readouts of receptor activation, offering biologically relevant data that cannot be captured by physicochemical methods alone
Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)